Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -25.11 Million EUR | 41.01% |
| 2022 | -42.57 Million EUR | -12.85% |
| 2021 | -37.72 Million EUR | 32.58% |
| 2020 | -55.95 Million EUR | -530.71% |
| 2019 | 12.99 Million EUR | 94.65% |
| 2018 | 6.67 Million EUR | 2.21% |
| 2017 | 6.53 Million EUR | 187.92% |
| 2016 | 2.26 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -37.48 Million EUR | 0.52% |
| 2023 Q3 | -28.89 Million EUR | 22.92% |
| 2023 Q1 | -37.68 Million EUR | 11.49% |
| 2023 FY | -25.11 Million EUR | 41.01% |
| 2023 Q4 | -28.65 Million EUR | 0.83% |
| 2022 Q1 | -50.82 Million EUR | -34.73% |
| 2022 Q2 | -57.62 Million EUR | -13.37% |
| 2022 Q3 | -32.71 Million EUR | 43.23% |
| 2022 FY | -42.57 Million EUR | -12.85% |
| 2022 Q4 | -42.57 Million EUR | -30.15% |
| 2021 Q1 | -45.16 Million EUR | 19.35% |
| 2021 FY | -37.72 Million EUR | 32.58% |
| 2021 Q4 | -37.72 Million EUR | 8.63% |
| 2021 Q3 | -41.28 Million EUR | 22.59% |
| 2021 Q2 | -53.33 Million EUR | -18.09% |
| 2020 Q4 | -55.99 Million EUR | 0.0% |
| 2020 Q3 | -55.99 Million EUR | 4.08% |
| 2020 Q1 | 15.62 Million EUR | 20.68% |
| 2020 FY | -55.95 Million EUR | -530.71% |
| 2020 Q2 | -58.37 Million EUR | -473.63% |
| 2019 Q3 | 12.94 Million EUR | 0.0% |
| 2019 Q4 | 12.94 Million EUR | 0.0% |
| 2019 FY | 12.99 Million EUR | 94.65% |
| 2019 Q1 | 2.68 Million EUR | 0.0% |
| 2018 FY | 6.67 Million EUR | 2.21% |
| 2017 FY | 6.53 Million EUR | 187.92% |
| 2016 FY | 2.26 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -3417.087% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 87.219% |
| Adocia SA | 127 Thousand EUR | 19873.228% |
| Aelis Farma SA | -16.19 Million EUR | -55.089% |
| Biophytis S.A. | 2.7 Million EUR | 1029.042% |
| Advicenne S.A. | 12.17 Million EUR | 306.259% |
| genOway Société anonyme | 2.97 Million EUR | 944.677% |
| IntegraGen SA | -709.74 Thousand EUR | -3438.152% |
| Medesis Pharma S.A. | 1.15 Million EUR | 2268.173% |
| Neovacs S.A. | -237.08 Thousand EUR | -10491.892% |
| NFL Biosciences SA | -2.27 Million EUR | -1003.402% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 676.425% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -2923.546% |
| Sensorion SA | 1.37 Million EUR | 1922.058% |
| Theranexus Société Anonyme | 2.44 Million EUR | 1127.431% |
| TME Pharma N.V. | -1.07 Million EUR | -2227.34% |
| Valbiotis SA | -18.13 Million EUR | -38.442% |
| TheraVet SA | 12.78 Thousand EUR | 196517.677% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 1251.927% |
| argenx SE | -1.83 Billion EUR | 98.633% |
| BioSenic S.A. | 28.04 Million EUR | 189.545% |
| Celyad Oncology SA | -6.1 Million EUR | -311.537% |
| DBV Technologies S.A. | -114.95 Million USD | 78.155% |
| Galapagos NV | -157.2 Million EUR | 84.026% |
| Genfit S.A. | -7.61 Million EUR | -229.944% |
| GeNeuro SA | 5.91 Million EUR | 524.878% |
| Innate Pharma S.A. | -30.71 Million EUR | 18.234% |
| Inventiva S.A. | 10.48 Million EUR | 339.413% |
| MaaT Pharma SA | -10.2 Million EUR | -146.075% |
| MedinCell S.A. | 39.5 Million EUR | 163.573% |
| Nanobiotix S.A. | -24.71 Million EUR | -1.594% |
| Onward Medical N.V. | -12.89 Million EUR | -94.757% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1855.674% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 192.565% |
| Oxurion NV | 10.71 Million EUR | 334.472% |
| Pharming Group N.V. | 99.4 Million EUR | 125.263% |
| Poxel S.A. | 44.55 Million EUR | 156.357% |
| GenSight Biologics S.A. | 16.29 Million EUR | 254.118% |
| Transgene SA | -14.4 Million EUR | -74.28% |
| Financière de Tubize SA | 78.62 Million EUR | 131.939% |
| UCB SA | 2.17 Billion EUR | 101.154% |
| Valneva SE | 82.73 Million EUR | 130.352% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -35.565% |